Finally, the selective targeting of BRAF activating mutations, which occur in about half of melanomas, with vemurafenib, dabrafenib, and trametinib, is associated with marked clinical activity and improved OS compared with chemotherapy [13, 14]. The gene discussed is BRAF; the disease is melanoma.